peptideInjectableNot FDA-approvedResearch chemicalNot FDA-approved as a therapeutic agent; the clinical literature on VIP mainly concerns diagnosing and managing VIP-secreting tumors (VIPoma) rather than administering VIP itselfSold in some markets as a research peptide despite the absence of human dosing trials in the cited record
VIPBenefits, Dosage & Interactions
Also known as: Vasoactive Intestinal Peptide
Vasoactive Intestinal Peptide (VIP) is a naturally occurring peptide composed of 28 amino acids. It was initially isolated from porcine duodenum due to its potent vasodilatory effects. Research on VIP focuses on tissue recovery and cognition and mood. VIP is administered by injection rather than orally.
How much VIP do people take?
No standardized therapeutic human dose exists; VIP is discussed in the cited literature primarily as an endogenous signaling peptide and as the causative hormone in VIPoma tumors, not as an administered drug with an established dose range. Route reported: Endogenous peptide; experimental administration in the cited animal model was systemic injection, not a human clinical route. Frequency reported: Not established for human use in the cited sources. These are amounts documented in the cited studies and labels for VIP — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Limited — Human observational or case data only — no randomized trials.
Evidence strengthLimited · 2/4
PreclinicalStrong human evidence
Human observational or case data only — no randomized trials.
Plasma half-life
1–2 min
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- No standardized therapeutic human dose exists; VIP is discussed in the cited literature primarily as an endogenous signaling peptide and as the causative hormone in VIPoma tumors, not as an administered drug with an established dose range[1][3]
Reported for VIP in the cited sources. Published ranges are not dosing advice.
Mixing VIP: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, VIP vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the VIP entry is written from. Each number matches an inline marker above.
- [1]Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in metabolic disorders and cancerMoody TW, Jensen RT · Current Opinion in Endocrinology, Diabetes, and Obesity · 2021 · Peer-reviewed · PMID 33481421
- [2]Vasoactive Intestinal Peptide-Secreting Tumors: A ReviewSiddappa PK, Vege SS · Pancreas · 2019 · Peer-reviewed · PMID 31609932
- [3]Vasoactive intestinal peptide exerts therapeutic action by regulating PTEN in a model of Sjögren's diseaseLi Y, Zhu W, Lin R, Zhao J, Wang Y · Immunity, Inflammation and Disease · 2023 · Peer-reviewed · PMID 37506142
References & Evidence
Sources on this page that document VIP dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is VIP studied for?
What is VIP?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Vasoactive Intestinal Peptide (VIP) is a naturally occurring peptide composed of 28 amino acids. It was initially isolated from porcine duodenum due to its potent vasodilatory effects. VIP belongs to the glucagon–secretin family of peptides, a group characterized by their structural similarities and diverse biological functions. Beyond its role in vasodilation, VIP is widely distributed throughout the body, acting as a hormone, neurotransmitter, and neuromodulator. It is found in significant concentrations in the central and peripheral nervous systems, the gastrointestinal tract, and the immune system. VIP exerts its effects by binding to specific G protein-coupled receptors, primarily VPAC1 and VPAC2, which are expressed on cell surfaces across various tissues. The widespread distribution of VIP and its receptors underscores its involvement in a broad spectrum of physiological processes, including the regulation of blood flow, digestion, inflammation, immune responses, and neuronal activity, as noted by research cited in PubMed Central articles and review articles on peptide hormones.
What does the research say about VIP?
Tap a section to expand.
VIP primarily exerts its physiological effects by activating specific G protein-coupled receptors, VPAC1 and VPAC2. Upon binding to these receptors, VIP initiates intracellular signaling cascades, predominantly through the activation of adenylate cyclase, which leads to an increase in cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP then activates protein kinase A (PKA), which phosphorylates various proteins within the cell, leading to a diverse range of cellular responses. For instance, in smooth muscle cells, this pathway leads to relaxation and vasodilation. In the gastrointestinal tract, VIP modulates smooth muscle contraction and glandular secretion. In the nervous system, VIP acts as a neurotransmitter, influencing neuronal excitability and synaptic plasticity. Its neuroprotective effects are thought to involve the modulation of inflammatory pathways and the promotion of neuronal survival. Furthermore, VIP has immunomodulatory properties, influencing cytokine production and immune cell function, as detailed in pharmacology textbooks and scientific literature indexed in databases like PubMed.
Source for this section: Sources for How does VIP work?: Jumps to this entry in the sources and references list at the end of the page.
Research has investigated the potential roles of Vasoactive Intestinal Peptide (VIP) in several physiological and pathological contexts:
* **Cardiovascular Regulation:** VIP is a potent vasodilator, meaning it can relax blood vessels and increase blood flow. This property has led to studies exploring its potential in conditions related to impaired blood supply or hypertension, as discussed in cardiovascular physiology literature.
* **Gastrointestinal Function:** VIP plays a significant role in regulating digestive processes. It influences gut motility, glandular secretions, and local blood flow within the gastrointestinal tract. Studies suggest its involvement in maintaining gut barrier integrity and modulating inflammatory responses in the digestive system, according to gastrointestinal research articles.
* **Neuroprotection and Brain Health:** VIP is widely present in the brain and nervous system, where it acts as a neurotransmitter and neuromodulator. Preclinical studies have explored its potential neuroprotective effects, suggesting it may help protect neurons from damage and support neuronal survival under certain stress conditions. This is an area of ongoing research, as outlined in neuroscience publications.
* **Anti-inflammatory and Immunomodulatory Effects:** VIP has demonstrated anti-inflammatory properties in various experimental models. It can modulate the production of pro-inflammatory cytokines and influence the activity of immune cells. This immunomodulatory role suggests potential therapeutic avenues in inflammatory and autoimmune conditions, although these are largely explored in preclinical settings, as noted in immunology journals.
* **Respiratory System:** VIP is also found in the respiratory tract where it contributes to bronchodilation. Research has investigated its role in conditions like asthma, though clinical applications are not yet established, according to respiratory medicine studies.
Individual needs vary — talk to a licensed clinician.
The understanding of Vasoactive Intestinal Peptide (VIP) and its physiological roles is primarily supported by extensive **preclinical research** conducted in cell culture and animal models. These studies have elucidated VIP's mechanisms of action at the molecular and cellular levels, and have demonstrated its diverse effects across various organ systems. For example, animal models of inflammation, ischemia, and neurodegenerative diseases have been used to investigate VIP's potential therapeutic properties, as detailed in numerous articles in journals accessible via PubMed.
**Human observational studies** and research on tissue samples have confirmed the presence and functional significance of VIP in human physiology. For instance, VIP levels are measured in contexts such as irritable bowel syndrome (IBS) or certain neuroendocrine tumors, providing insights into its involvement in health and disease, as reported by clinical research publications.
While VIP has been the subject of **early-phase clinical trials** for specific conditions, such as pulmonary arterial hypertension and inflammatory conditions, its broader application as a therapeutic agent is still under investigation. These trials aim to assess safety and preliminary efficacy, but comprehensive **large-scale, randomized controlled trials** necessary for establishing widespread clinical use are limited or ongoing. Therefore, much of the evidence regarding VIP's benefits to human health remains primarily at the preclinical and early translational stages, as indicated by clinical trial registries and research reviews, such as those found on ClinicalTrials.gov or through systematic reviews on platforms like Cochrane Library.
Reported side effects associated with Vasoactive Intestinal Peptide (VIP) administration, particularly in research settings involving intravenous or subcutaneous routes, can include:
* **Vasodilation-related effects:** Due to its primary action as a vasodilator, some individuals may experience a temporary decrease in blood pressure, flushing, or headache. These effects are generally transient and dose-dependent.
* **Gastrointestinal upset:** Nausea, abdominal discomfort, or changes in bowel habits have been reported in some studies, reflecting VIP's influence on the digestive system.
* **Heart rate changes:** Transient increases in heart rate have been observed in some instances, likely a compensatory response to vasodilation.
* **Localized reactions:** For injectable forms, mild pain, redness, or swelling at the injection site are possible, as with most injectable compounds.
The occurrence and severity of side effects can vary depending on the individual, the route of administration, and the studied dose range. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
When considering Vasoactive Intestinal Peptide (VIP), it's important to be aware of potential considerations and warnings:
* **Blood Pressure:** Due to its vasodilatory properties, VIP can cause a decrease in blood pressure. Individuals with pre-existing low blood pressure or those taking medications that also lower blood pressure should exercise caution and be monitored by a healthcare professional.
* **Interactions with Medications:** VIP's effects on blood vessels and various organ systems suggest a potential for interactions with other medications, particularly those affecting cardiovascular function, gastrointestinal motility, or immune responses. Specific interactions would need to be evaluated in a clinical context.
* **Research Compound:** VIP is primarily a research compound, and its clinical use is not broadly established for most conditions. Information regarding long-term safety and efficacy in humans is still developing.
* **Allergic Reactions:** As with any peptide or administered substance, there is a theoretical risk of allergic or hypersensitivity reactions.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the ongoing research nature of Vasoactive Intestinal Peptide (VIP) and limited widespread clinical use, definitive contraindications are not as extensively established as for approved medications. However, based on its known pharmacological actions, potential contraindications or situations where extreme caution would be advised include:
* **Severe Hypotension:** Individuals with profoundly low blood pressure or conditions that put them at risk for severe drops in blood pressure may be contraindicated due to VIP's vasodilatory effects.
* **Known Hypersensitivity:** A history of allergic reaction or hypersensitivity to Vasoactive Intestinal Peptide or any components of its formulation would be a contraindication.
* **Certain Cardiovascular Conditions:** While VIP has been researched for cardiovascular benefits, conditions where acute vasodilation could be detrimental (e.g., specific forms of shock or severe heart failure where maintaining vascular tone is critical) would require careful medical evaluation.
* **Pregnancy and Lactation:** Due to insufficient data on safety in pregnant or breastfeeding individuals, VIP is generally contraindicated in these populations, aligning with standard practice for compounds lacking extensive safety profiles.
* **Specific Medical Conditions:** Conditions where alterations in gastrointestinal motility, hormone levels, or immune responses could be destabilizing or detrimental might also present contraindications. A thorough medical assessment is necessary.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to its complex physiological effects, Vasoactive Intestinal Peptide (VIP) may interact with various medications and compounds. While specific contraindications for mixing are still largely in the realm of clinical research, potential areas of concern include:
* **Antihypertensive Medications:** Combining VIP with drugs that also lower blood pressure (e.g., ACE inhibitors, ARBs, calcium channel blockers, diuretics) could potentially lead to an excessive drop in blood pressure. Monitoring would be essential.
* **Vasoconstrictors:** Administering VIP concurrently with compounds that cause vasoconstriction (narrowing of blood vessels) might lead to opposing physiological effects, potentially counteracting the intended action of either substance or leading to unpredictable cardiovascular responses.
* **Immunosuppressants or Immunostimulants:** Given VIP's immunomodulatory properties, its co-administration with drugs that significantly alter immune function could lead to complex and potentially undesirable interactions. This area often requires careful consideration in research settings.
* **Gastrointestinal Motility Modifiers:** As VIP affects gut motility, combining it with medications that either enhance or suppress gastrointestinal movement could alter their effectiveness or introduce unforeseen side effects.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Vasoactive Intestinal Peptide (VIP) is typically studied in research settings without a universally established "best" timing for administration, as its use is highly dependent on the specific research protocol and desired physiological outcome. When administered in a clinical research context, the timing of VIP is often determined by the pharmacokinetics of the compound and the specific condition being investigated.
For compounds with a relatively short half-life, such as VIP, more frequent administration or continuous infusion might be considered in research to maintain consistent levels, if that is the goal of the study. Due to its short half-life of approximately 1 minute in circulation, as noted in pharmacology references, continuous intravenous infusion is often used in research studies aiming for sustained systemic effects. Subcutaneous administration or other sustained-release formulations, if developed, might allow for less frequent dosing.
There are no specific food rules associated with VIP administration, as its absorption and systemic effects via injection are not typically influenced by the presence or absence of food. Decisions regarding timing are currently investigator-directed and must be set by a licensed clinician within a research protocol.
Source for this section: Sources for When should you take VIP?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about VIP is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with VIP?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about VIP
Vasoactive Intestinal Peptide (VIP) is a naturally occurring peptide in the body made of 28 amino acids. It acts as a hormone and neurotransmitter, involved in various bodily functions like regulating blood flow, digestion, and immune responses. It was first discovered for its ability to relax blood vessels.
VIP has multiple roles in the body. It causes blood vessels to widen (vasodilation), affects muscle contractions and secretions in the digestive system, acts as a messenger in the nervous system, and can influence immune cell activity and inflammation. Its widespread distribution means it impacts many different physiological processes.
While Vasoactive Intestinal Peptide (VIP) has been extensively studied in preclinical research and some early-phase clinical trials, it is not broadly approved or used as a standard medication for most conditions. Its use is primarily within advanced research and investigational settings, as documented in clinical trial databases.
In research settings, administration of VIP can lead to side effects such as a temporary drop in blood pressure, flushing, headache, or mild gastrointestinal discomfort. Localized reactions like pain or redness at the injection site are also possible. These effects are generally transient and depend on the dose and individual.
In research and investigational contexts, VIP is typically administered via injection, often intravenously (into a vein) or subcutaneously (under the skin). Due to its short half-life, continuous intravenous infusion may be used in studies requiring sustained systemic levels, as described in pharmacology and clinical research protocols.
Interaction risk for VIP comes from the rest of the stack: other peptides, prescription medicines, hormone therapy and peptides. With a reported plasma half-life near 0.016666666666666666 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers VIP with no sign-up.
VIP is administered by injection, so the measured volume — not a tablet count — is the unit that matters. The reported plasma half-life is about 0.016666666666666666 hours, which is what drives how often it is redosed. Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for VIP plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
A short plasma half-life of roughly 0.016666666666666666 hours is why protocols often split VIP across the day rather than using a single dose. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because VIP clears quickly (plasma half-life around 0.016666666666666666 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like VIP the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
No standardized therapeutic human dose exists; VIP is discussed in the cited literature primarily as an endogenous signaling peptide and as the causative hormone in VIPoma tumors, not as an administered drug with an established dose range. Route reported: Endogenous peptide; experimental administration in the cited animal model was systemic injection, not a human clinical route. Frequency reported: Not established for human use in the cited sources. These are amounts documented in the cited studies and labels for VIP — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at VIP?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects.(opens PubMed in a new tab)Gut · 1978 · PMID 730072 · https://pubmed.ncbi.nlm.nih.gov/730072/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 102602038(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/102602038
Verify at
Publisher search links for VIP. These are places to check the information — they are not citations, so they are not numbered.
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- ClinicalTrials.gov(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on VIP?
Plain-text summary, safe to quote verbatim:
Vasoactive Intestinal Peptide (VIP) is a naturally occurring peptide composed of 28 amino acids. It was initially isolated from porcine duodenum due to its potent vasodilatory effects. Research on VIP focuses on tissue recovery and cognition and mood. VIP is administered by injection rather than orally.
Source: DoseRoutine — https://doseroutine.com/library/vip
VIP cheat sheet
DoseRoutine cheat sheet · Peptide
VIP
Vasoactive Intestinal Peptide (VIP) is a naturally occurring peptide composed of 28 amino acids. It was initially isolated from porcine duodenum due to its potent vasodilatory effects.
Evidence
Limited
Human observational or case data only — no randomized trials.
Studied range
No standardized therapeutic human dose exists; VIP is discussed in the cited literature primarily as an endogenous signaling peptide and as the causative hormone in VIPoma tumors, not as an administered drug with an established dose range
Route
Endogenous peptide; experimental administration in the cited animal model was systemic injection, not a human clinical route
Frequency studied
Not established for human use in the cited sources
Half-life
1–2 min
Not FDA-approvedResearch chemicalNot FDA-approved as a therapeutic agent; the clinical literature on VIP mainly concerns diagnosing and managing VIP-secreting tumors (VIPoma) rather than administering VIP itselfSold in some markets as a research peptide despite the absence of human dosing trials in the cited recordRecoveryBrain
Key references
- Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in metabolic disorders and cancer (2021)
- Vasoactive Intestinal Peptide-Secreting Tumors: A Review (2019)
- Vasoactive intestinal peptide exerts therapeutic action by regulating PTEN in a model of Sjögren's disease (2023)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/vip
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). VIP — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/vip
What compounds are similar to VIP?
Others in the peptide category or studied for the same goals.
Which goals is VIP used for?
Other compounds studied for the same benefits as VIP.
Recovery & Healing
See all →Continue exploring
See every compound DoseRoutine catalogs for these goals.